Reading the UK’s 2019 medtech regulations–created in anticipation of a no-deal Brexit at the end of March–is a tough slog. So Medtech Insight spoke directly to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to find out the essentials. What changes would enable UK medtech rules to fully function in a no-deal Brexit scenario? What are the other crucial points in the 224-page document? Find out the key takeaways, and whether you really have to read and digest the whole thing. Find out what else MHRA had to say.